Psoriatic arthritisDifferences in the Patient's and the Physician's Perspective of Disease in Psoriatic Arthritis
Section snippets
Patients and Assessment Tools
55 PsA patients participated in the present study at the Department of Internal Medicine 3 of the University of Erlangen-Nuremberg. All patients were enrolled consecutively, met the Classification Criteria for Psoriatic Arthritis (19, 20), and were evaluated, regardless of their actual disease activity or medical history. Correspondingly, all participants were subjected to a detailed clinical examination as well as a completion of several patient-reported outcome measures consisting of 4 panels
Patients and Disease Characteristics
Our cohort consisted of 55 PsA patients, 27 of them women (mean age 51.72 ± 11.15 years; mean duration of disease 5.52 ± 5.34 years) and 28 men (mean age 51.44 ± 13.76 years; mean duration of disease 6.25 ± 7.45 years), with an overall mean age of 51.22 ± 12.21 years and an overall mean duration of disease of 5.92 ± 6.61 years. On average, our patients were evaluated to have 13 tender (12.91 ± 14.54) and 4 swollen joints (4.07 ± 4.93). The mean global pain score was 3.81 ± 2.82. Enthesial
Discussion
PsA is a complex disease with symptoms ranging from musculoskeletal disease, skin and nail disease, to systemic symptoms such as fatigue. Thus, the overall state of disease in PsA represents the sum of these individual components, their objective severity, and the way the patients experience these symptoms. Based on the complexity of PsA, the physician's evaluation of disease activity may not fully reflect the implicit burden of PsA for the patients. They may perceive and thus weigh an
References (32)
- et al.
Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis
J Am Acad Dermatol
(2003) - et al.
Psoriasis
N Engl J Med
(2005) - et al.
Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis
Br J Dermatol
(2009) Prevalence of joint disease in patients with psoriasis: implications for therapy
Am J Clin Dermatol
(2003)- et al.
Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials
J Rheumatol
(2008) - et al.
Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology
Clin Exp Rheumatol
(2011) - et al.
Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study
Arthritis Rheum
(2009) Spondyloarthritis update: new insights regarding classification, pathophysiology, and management
Bull NYU Hosp Jt Dis
(2008)- et al.
Composite measures in psoriatic arthritis: GRAPPA 2008
J Rheumatol
(2010) - et al.
Consensus on a core set of domains for psoriatic arthritis
J Rheumatol
(2007)
Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study
J Rheumatol
International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis
Arthritis Rheum
International spondyloarthritis interobserver reliability exercise–the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis
J Rheumatol
The clinical assessment of patients with psoriatic arthritis: results of a reliability study of the spondyloarthritis research consortium of Canada
J Rheumatol
Reliability of measurements of active and damaged joints in psoriatic arthritis
J Rheumatol
Operational definitions and observer reliability of the plain radiographic features of psoriatic arthritis
J Rheumatol
Cited by (39)
Prospective Blinded Evaluation of Patient-Physician Agreement Using the Summary Outcome Determination (SOD) Score
2019, Mayo Clinic ProceedingsCitation Excerpt :This study demonstrates that patients and providers can agree on the outcome of a surgery, which implies that doctors are capable of understanding a patient’s values. This finding is important because substantial disagreement between physicians and patients has been reported in areas such as quality of life, disease severity, and pain, with physicians routinely underestimating these subjective findings.28-35 In other words, physicians tend to view the results of surgery more favorably than their patients do.
Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study
2019, Seminars in Arthritis and RheumatismCitation Excerpt :This situation bears substantial limitations since not all PsA patients are characterized by polyarticular disease. Furthermore, enthesitis is a major source of pain, functional disability and reduced life quality in patients, suggesting that studies in enthesitis-driven PsA patients are urgently required [22–25]. New concepts suggest that enthesitis is based on a distinct molecular pathology.
The association of clinical parameters and ultrasound verified inflammation with patients’ and physicians’ global assessments in psoriatic arthritis
2016, Seminars in Arthritis and RheumatismCitation Excerpt :Accordingly, these recommendations suggest to adapt treatment in case of active inflammation, and to share treatment decisions between patients and physicians [2,3]. The perception of disease activity of patients and physicians, however, is not always overlapping, and given that physicians tend to trust in their own ratings more (regardless whether they are better or worse) than in those of patients, decisions are prone not to be shared [4–9]. The reliable assessment of disease activity in PsA is challenging.
Clinimetrics in Sjögren's syndrome
2019, Revista Colombiana de Reumatologia